Multiple Sclerosis Clinical Trial
Official title:
Effects of a 12-week Inspiratory Muscle Training Program With Low Resistance in Patients With Multiple Sclerosis
Objective: To evaluate the effectiveness of a low-intensity protocol of inspiratory muscle
training (IMT) to improve respiratory strength, spirometric parameters and dyspnea in
patients with multiple sclerosis (MS).
Design: Clinical trial. Randomized. Participants: 67 patients with MS, distributed in two
groups, intervention and control.
Intervention: Intervention group train using IMT for 12 weeks, 5 days/week, 15 minutes/day
(20% maximum inspiratory pressure (MIP) during the first two weeks and 30% MIP after the
second week). Control group follow a respiratory exercise program involving nasal breathing
and maximum exhalation during 12 weeks, 5 days/week, 15 minutes/day.
Evaluations: Determination of the MIP and the maximum expiratory pressure (MEP); spirometry -
maximum voluntary ventilation (MVV), peak expiratory flow (PEF), tidal volume (TV); dyspnea
using the Borg scale and clinical evaluations.
Participants:
Patients from two MS associations will be recruited to participate in a 12-week randomized
trial.
The sample size calculation determine that 31 participants in each group are required to
observe a minimum difference in the maximum inspiratory pressure (MIP) of 12 cm H2O,
considering a power of 90%, a safety of 95% and a 10% dropout rate.
The participants in the study are diagnosed with MS, are over 18 years old, have a disability
lower than 9 in the Expanded disability status scale (EDSS) and are able to understand the
objectives of the study. Those participants with a current or past neurological pathology
other than MS will be excluded from the study, as well as those who had had a relapse of MS
or any respiratory pathology during the 4 weeks prior to the start of the study, or any other
complication that may have impeded the performance of the evaluation tests or breathing
techniques. All patients will be asked to carry out the 5-day weekly program at home, and a
recording sheet will be provided to each participant so they will can record the time of each
daily respiratory training session. All participants signed an informed consent form.
The patients will be assigned to the two groups randomly. The main researcher doesn´t meet
any of the participants until the initial assessment will be carried out. The intervention
group (n = 36) will receive a training protocol of IMT, while the control group (n = 31) will
follow a program of nasal breathing and maximum exhalations.
Evaluation:
The participants are evaluated at the beginning and end of the intervention period.
The evaluation of MIP and MEP is performed using a pressure transducer, Elka 15, which
obtains each measurement in millibar and converts it into the reference unit of centimeter of
water (cm H2O) (1 mbar = 1.01973 cm H2O .), following the rules of the American thoracic
society/European respiratory society (ATS / ERS) [19]. The procedure will be repeated until 3
values were obtained with a difference of less than 5%, and the highest value will be used
for the analysis. The MIP of the intervention group will be assessed every 2 weeks to set the
IMT workload.
Lung volumes are assessed using a datospir touch spirometer with a turbine transducer with a
maximum flow of 16 l/s and a maximum volume of 10 l. The ATS/ERS rules will be followed [19],
and the highest value of three correct measurements will be chosen. Data is collected for the
following parameters: maximum voluntary ventilation (MVV), forced expiratory volume in the
first second (FEV1), peak expiratory flow (PEF), mean expiratory flow (FEF25-75), vital
capacity (VC), tidal volume (TV) and forced vital capacity (FVC).
Dyspnea will be measured using the modified Borg scale [20]. All evaluations will be done in
the corresponding center, during the same time slot and by the same examiner for both groups.
Intervention:
For the intervention group, a protocol different from those referred to in the literature has
been designed to cover the respiratory deficiencies of MS patients using IMT. The device
incorporates a unidirectional valve independent of flow to guarantee constant resistance and
includes a specific pressure setting (in cm H2O). During the first two weeks a MIP load of
20% will be used, followed by a load of 30% for the rest of the training period. The protocol
includes 15 cycles lasting 1 minute, twice a day: one in the morning and one in the
afternoon. The participants rest for 1 minute between each cycle. In total, the protocol
includes 30 minutes of daily respiratory training. The patients will be instructed to inhale
with enough force to reach the opening of the valve.
The training program of the control group involves nasal inhalations and maximum exhalations.
The following types of breathing exercises will be carried out for 3 minutes each with a 1
minute pause for resting: abdominal breathing, chest breathing, breathing and shoulder
flexion, shoulder breathing and abduction, breathing and shoulder abduction in the transverse
plane. The complete protocol involves 30 minutes of daily respiratory training.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT03269175 -
BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies
|
Phase 4 |